Zentalis Pharmaceuticals Inc (ZNTL)

$8.39

-0.45

(-5.09%)

Market is closed - opens 7 PM, 18 Jun 2024

Insights on Zentalis Pharmaceuticals Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 76.7% return, outperforming this stock by 144.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 244.3% return, outperforming this stock by 327.3%

Performance

  • $8.31
    $8.84
    $8.39
    downward going graph

    1.01%

    Downside

    Day's Volatility :6.05%

    Upside

    5.09%

    downward going graph
  • $8.39
    $30.53
    $8.39
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :72.52%

    Upside

    72.52%

    downward going graph

Returns

PeriodZentalis Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-36.22%
0.4%
0.0%
6 Months
-36.31%
8.7%
0.0%
1 Year
-69.0%
10.3%
0.0%
3 Years
-82.98%
16.5%
-22.7%

Highlights

Market Capitalization
676.0M
Book Value
$6.46
Earnings Per Share (EPS)
-3.26
Wall Street Target Price
33.4
Profit Margin
0.0%
Operating Margin TTM
-61.06%
Return On Assets TTM
-24.93%
Return On Equity TTM
-51.87%
Revenue TTM
40.6M
Revenue Per Share TTM
0.59
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-207.4M
Diluted Eps TTM
-3.26
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.75
EPS Estimate Next Year
-3.71
EPS Estimate Current Quarter
-0.77
EPS Estimate Next Quarter
-0.94

Analyst Recommendation

Buy
    82%Buy
    17%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Zentalis Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
14
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 298.09%

Current $8.39
Target $33.40

Technicals Summary

Sell

Neutral

Buy

Zentalis Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
-26.76%
-36.31%
-69.0%
-82.98%
-61.9%
Moderna, Inc.
Moderna, Inc.
5.36%
63.93%
12.72%
-30.84%
787.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.52%
21.82%
32.68%
93.38%
233.31%
Novo Nordisk A/s
Novo Nordisk A/s
8.04%
43.97%
76.29%
244.33%
458.71%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
7.98%
18.8%
40.28%
155.22%
176.63%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
NA
NA
NA
-2.75
-0.52
-0.25
NA
6.46
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.71
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.32
30.32
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.73
49.73
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.07
31.07
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
Buy
$676.0M
-61.9%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$55.7B
787.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$113.1B
233.31%
30.32
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$634.9B
458.71%
49.73
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$123.6B
176.63%
31.07
39.46%

Institutional Holdings

  • Matrix Capital Management Company, LLC

    19.66%
  • Eventide Asset Management, LLC

    16.30%
  • FMR Inc

    14.56%
  • BlackRock Inc

    6.60%
  • State Street Corporation

    6.22%
  • Vanguard Group Inc

    6.19%

Company Information

developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer

Organization
Zentalis Pharmaceuticals Inc
Employees
124
CEO
Dr. Kimberly Lynn Blackwell M.D.
Industry
Health Technology

FAQs